10,386 results match your criteria American Journal Of Hematology[Journal]


Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial.

Am J Hematol 2022 May 26. Epub 2022 May 26.

Policlinic G.B. Rossi Borgo Rome, Verona, Italy.

The phase III study was designed to compare event-free survival (EFS) after treosulfan-based conditioning with a widely applied reduced-intensity conditioning (RIC) busulfan regimen in older or comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). A previously reported confirmatory interim analysis of the randomized clinical study including 476 patients demonstrated statistically significant non-inferiority for treosulfan with clinically meaningful improvement in EFS. Here, the final study results and pre-specified subgroup analyses of all 570 randomized patients with completed longer term follow-up are presented. Read More

View Article and Full-Text PDF

Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses.

Am J Hematol 2022 May 24. Epub 2022 May 24.

Haematology Department, Concord Repatriation General Hospital, Sydney, NSW, Australia.

Patients with indolent lymphoma undertaking recurrent or continuous B cell suppression are at risk of severe COVID-19. Patients and healthy controls (HC; N=13) received 2 doses of BNT162b2: Follicular Lymphoma (FL; N=35) who were treatment naïve (TN; N=11) or received immunochemotherapy (ICT; N=23) and Waldenström's Macroglobulinemia (WM; N=37) including TN (N=9), ICT (N=14), or treated with Bruton's Tyrosine Kinase inhibitors (BTKi; N=12). Anti-spike IgG was determined by a high-sensitivity flow-cytometric assay, in addition to live-virus neutralization. Read More

View Article and Full-Text PDF

Vaccination does not affect leukocyte morphologic abnormalities of severe COVID-19.

Am J Hematol 2022 May 23. Epub 2022 May 23.

Catholic University of Sacred Heart, Facoltà di Medicina e Chirurgia, Rome, Italy.

View Article and Full-Text PDF

Aspirin Prophylaxis for Hereditary and Acquired Thrombotic Thrombocytopenic Purpura?

Am J Hematol 2022 May 20. Epub 2022 May 20.

Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.

View Article and Full-Text PDF

Assessment of donor cell engraftment after hematopoietic stem cell transplantation for sickle cell disease: A review of current and future methods.

Am J Hematol 2022 May 18. Epub 2022 May 18.

Department of Pediatrics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB, Canada.

Hematopoietic stem cell transplantation (HSCT) is the only established curative treatment for sickle cell disease (SCD), a debilitating red blood cell (RBC) disorder with significant prevalence worldwide. Accurate assessment of RBC engraftment following HSCT is essential to evaluate the status of the graft and can enable early intervention to treat or prevent graft rejection. Currently, chimerism measurement is performed on whole blood samples, which mainly reflect white blood cell chimerism. Read More

View Article and Full-Text PDF

Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia.

Am J Hematol 2022 May 18. Epub 2022 May 18.

Department of Leukemia.

Background: Multi-agent induction chemotherapy (IC) improves response rates in younger patients with acute myeloid leukemia (AML), however relapse remains the principal cause of treatment failure. Improved induction regimens are needed.

Methods: A prospective single-center phase Ib/II study evaluating fludarabine, cytarabine, G-CSF, and idarubicin combined with venetoclax (FLAG-IDA+VEN) in patients with newly diagnosed (ND) or relapsed/refractory AML. Read More

View Article and Full-Text PDF

TP53-altered CLL Treated with Firstline Bruton's Tyrosine Kinase Inhibitor-based Therapy: A Retrospective Analysis.

Am J Hematol 2022 May 14. Epub 2022 May 14.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

Long-term follow up of prospective studies has shown that continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy leads to durable remissions in previously untreated patients with TP53-altered chronic lymphocytic leukemia (CLL); however, it is unknown how variant allele frequency (VAF) of TP53 mutation (TP53-m) or percentage of cells with deletion of chromosome 17p [del(17p)] influences efficacy of firstline BTKi. We performed a retrospective analysis of 130 patients with CLL with baseline del(17p) and/or TP53-m treated with BTKi with or without the BCL2 inhibitor venetoclax (VEN) and with or without CD20 antibody in the firstline setting. A total of 104/131 (79%) patients had del(17p). Read More

View Article and Full-Text PDF

Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.

Am J Hematol 2022 May 14. Epub 2022 May 14.

Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Early autologous hematopoietic cell transplantation (AHCT) with post-transplant maintenance therapy is standard of care in multiple myeloma (MM). While short-term quality of life (QOL) deterioration after AHCT is known, the long-term trajectories and symptom burden after transplantation are largely unknown. Toward this goal, a secondary analysis of QOL data of the BMT CTN 0702, a randomized controlled trial comparing outcomes of three treatment interventions after a single AHCT (N = 758), was conducted. Read More

View Article and Full-Text PDF

Hepato-splenic abscesses in a sickle cell disease patient.

Am J Hematol 2022 May 14. Epub 2022 May 14.

Department of Nephrology and Transplantation, Necker Enfant-Malades University Hospital, Assistance Publique Des Hôpitaux de Paris, Paris, France.

View Article and Full-Text PDF

Long-term outcomes of patients with conjunctival extranodal marginal zone lymphoma.

Am J Hematol 2022 May 12. Epub 2022 May 12.

Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA.

Comprehensive information on clinical features and long-term outcomes of primary conjunctival extranodal marginal zone lymphoma (PCEMZL) is scarce. We present a large single-institution retrospective study of 72 patients. The median age was 64 years, and 63. Read More

View Article and Full-Text PDF

Optical genome mapping for structural variation analysis in hematologic malignancies.

Am J Hematol 2022 May 12. Epub 2022 May 12.

Department of Hematopathology and Molecular Diagnostics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Optical genome mapping (OGM) is a technology that is rapidly being adopted in clinical genetics laboratories for its ability to detect structural variation (e.g., translocations, inversions, deletions, duplications, etc. Read More

View Article and Full-Text PDF

A CRISPR view of hematopoietic stem cells: Moving innovative bioengineering into the clinic.

Am J Hematol 2022 May 12. Epub 2022 May 12.

Institute for the Biology of Stem Cells, University of California-Santa Cruz, Santa Cruz, California, USA.

Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas genome engineering has emerged as a powerful tool to modify precise genomic sequences with unparalleled accuracy and efficiency. Major advances in CRISPR technologies over the last 5 years have fueled the development of novel techniques in hematopoiesis research to interrogate the complexities of hematopoietic stem cell (HSC) biology. In particular, high throughput CRISPR based screens using various "flavors" of Cas coupled with sequencing and/or functional outputs are becoming increasingly efficient and accessible. Read More

View Article and Full-Text PDF

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.

Am J Hematol 2022 May 12. Epub 2022 May 12.

Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

Disease Overview: Multiple myeloma accounts for approximately 10% of hematologic malignancies.

Diagnosis: The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy-proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE): CRAB (hypercalcemia, renal failure, anemia, or lytic bone lesions) attributable to the plasma cell disorder, bone marrow clonal plasmacytosis ≥60%, serum involved/uninvolved free light chain (FLC) ratio ≥ 100 (provided involved FLC is ≥100 mg/L), or >1 focal lesion on magnetic resonance imaging.

Risk Stratification: The presence of del(17p), t(4;14), t(14;16), t(14;20), gain 1q, or p53 mutation is considered high-risk multiple myeloma. Read More

View Article and Full-Text PDF

Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.

Am J Hematol 2022 May 12. Epub 2022 May 12.

Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, South Australia.

Therapy-related myeloid neoplasms (t-MN) are aggressive malignancies in need of effective therapies. The BCL-2 inhibitor venetoclax represents a paradigm shift in the treatment of acute myeloid leukemia. However, the effectiveness of venetoclax has not been studied in a large cohort of t-MN. Read More

View Article and Full-Text PDF

Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant.

Am J Hematol 2022 May 12. Epub 2022 May 12.

Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.

We designed a trial to simultaneously address the problems of graft versus host disease (GVHD), infection, and recurrence of malignancy after allogeneic stem cell transplantation. CD34 stem cell isolation was used to minimize the development of acute and chronic GVHD. Two prophylactic infusions, one combining donor-derived cytomegalovirus, Epstein-Barr virus, and Aspergillus fumigatus specific T-cells and the other comprising donor-derived CD19 directed chimeric antigen receptor (CAR) bearing T-cells, were given 21-28 days after transplant. Read More

View Article and Full-Text PDF

CORRIGENDUM.

Authors:

Am J Hematol 2022 May 10. Epub 2022 May 10.

View Article and Full-Text PDF

Unusual complications in the management of chronic lymphocytic leukemia.

Am J Hematol 2022 May 1. Epub 2022 May 1.

MD Anderson Cancer Center, University of Texas, Houston, Texas, USA.

Chronic lymphocytic leukemia (CLL) is a common, indolent disease that typically presents with a proliferation of mature, immunologically dysfunctional CD5+ B-cells which preferentially occupy the bone marrow, peripheral blood and lymphoid organs. Immune dysfunction leads to an increase in autoimmune diseases which occur in approximately 10% of patients with CLL. Autoimmune cytopenias are the most common, but other organs may be affected as well. Read More

View Article and Full-Text PDF

A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia.

Am J Hematol 2022 May 1. Epub 2022 May 1.

Hebei Yanda Lu Daopei Hospital, Langfang, China.

We developed a T-cell-receptor (TCR) complex-based chimeric antigen receptor (CAR) named Synthetic TCR and Antigen Receptor (STAR). Here, we report pre-clinical and phase I clinical trial data (NCT03953599) of this T-cell therapy for refractory and relapsed (R/R) B-cell acute lymphoblastic leukemia (B-ALL) patients. STAR consists of two protein modules each containing an antibody light or heavy chain variable region and TCR α or β chain constant region fused to the co-stimulatory domain of OX40. Read More

View Article and Full-Text PDF

CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.

Am J Hematol 2022 Apr 29. Epub 2022 Apr 29.

Department of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China.

In this open-label, single-arm, phase I/II clinical trial, we evaluated the efficacy of anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) therapy in 49 relapsed/refractory multiple myeloma (RRMM) patients, including 20 with Eastern Cooperative Oncology Group (ECOG) grade 3-4. After HDS269B infusion (9 × 10 CAR cells/kg), 17 patients (34.69%, 11 ECOG 0-2, 6 ECOG 3-4) developed cytokine release syndrome [grade 1-2: 14 patients (28. Read More

View Article and Full-Text PDF

Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma.

Am J Hematol 2022 Apr 28. Epub 2022 Apr 28.

Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

Altered energy metabolism and changes in glycolytic and oxidative phosphorylation pathways are hallmarks of all cancer cells. The expression of select genes associated with the production of various enzymes and proteins involved in glycolysis and oxidative phosphorylation were assessed in the clonal plasma cells derived from patients with newly diagnosed multiple myeloma (NDMM) enrolled in the Multiple Myeloma Research Foundation (MMRF) CoMMpass data set. A scoring system consisting of assigning a point for every gene where their fragments per kilobase of transcript per million (FPKM) was above the median yielded a minimum of 0 and a maximum of 12 for the set of genes in the glycolytic and oxidative phosphorylation pathways to create a total energy metabolism molecular signature (EMMS) score. Read More

View Article and Full-Text PDF

Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long-term outcomes in COVID-19 patients.

Am J Hematol 2022 Apr 28. Epub 2022 Apr 28.

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Sustained hypercoagulability and endotheliopathy are present in convalescent COVID-19 patients for up to 4 months from recovery. The hemostatic, endothelial, and inflammatory profiles of 39 recovered COVID-19 patients were evaluated up to 16 months after recovery from COVID-19. These values were compared with a control group of healthy volunteers (n = 124). Read More

View Article and Full-Text PDF

Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high- and low- to middle-income countries for the international Sickle Cell World Assessment Survey (SWAY).

Am J Hematol 2022 Apr 26. Epub 2022 Apr 26.

New England Sickle Cell Institute, University of Connecticut Health, Farmington, Connecticut.

The international Sickle Cell World Assessment Survey (SWAY) reported a high impact of sickle cell disease (SCD) on patients' daily lives globally. In this study we analyzed whether the reported burden differed between patients from the USA (n = 384) and other high-income (HI; n = 820) or low- to middle-income (LMI; n = 941) countries. We assessed symptoms and complications, incidence/management of vaso-occlusive crises (VOCs), treatment utilization/satisfaction, and the impact of SCD on education/employment. Read More

View Article and Full-Text PDF